Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 7/20 | 0.71 |
| ▸ | GABRD | O14764 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232368 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL29425001 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL23997518 | 0.89 | KDM4E (0.80) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL1366897 | 0.87 | KDM4E (0.77) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL2253820 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL11092278 | 0.85 | KMT2A (0.80) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL7383821 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL7384067 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL10857122 | 0.84 | GABRA1 (0.75) | ALDH1A1MAPTKDM4ELMNACYP1A2 | |
| SCHEMBL7381871 | 0.83 | KDM4E (0.71) | ALDH1A1MAPTKDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757378-B2 | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation | UNIVERSITE DE MONTREAL (CA) | 2017-09-12 | — | — | US | claimed |
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | HOPITAL MAISONNEUVE-ROSEMONT (CA) | 2014-11-20 | — | — | US | claimed |
| WO-2009049105-A2 | METHODS FOR INDUCING SATIATION | GELESIS, INC. (US) | 2009-04-16 | — | — | WO | claimed |
| US-5010077-A | Tranquilizers | A/S FERROSAN (DK) | 1991-04-23 | — | — | US | claimed |
| EP-0030254-B1 | BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-10-31 | — | — | EP | claimed |
| EP-0030254-A1 | Beta-carbolin-3-carboxylic acid derivatives, pharmaceutical compositions containing them and their therapeutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | claimed |
| US-20230320384-A1 | Methods and Compositions for Weight Management and for Improving Glycemic Control | GELESIS LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-3076987-B1 | METHOD OF TREATING OR PREVENTING EPILEPSY OR SEIZURES USING ONE OR MORE NEURAL REGENERATION PEPTIDES | CURONZ HOLDINGS COMPANY LTD (NZ) | 2023-07-12 | — | — | EP | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4038392-A1 | SCREENING WITH MASS SPECTROMETRY FOR MYCOBACTERIA PRIOR TO CARDIOTHORACIC SURGERY | Imperial College Innovations Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20210154169-A1 | INTRANASAL AND TRANSDERMAL ADMINISTRATION OF KAPPA-OPIOID-RECEPTOR AGONISTS: SALVINORIN A FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SOLOMON ATLEE (US) | 2021-05-27 | — | — | US | disclosed |
| US-4918084-A | ANXIOLYTIC AGENTS; BENZODIAZEPINE INVERSE AGONIST ANTAGONISTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-04-17 | — | — | US | disclosed |
| US-4835151-A | ANXIOLYTIC AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-05-30 | — | — | US | disclosed |
| US-4738973-A | ANXIOLYTIC AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-04-19 | — | — | US | disclosed |
| EP-0216555-A2 | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections | BTG INTERNATIONAL LIMITED (GB) | 1987-04-01 | — | — | EP | disclosed |
| EP-0030254-B1 | BETA-CARBOLIN-3-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-10-31 | — | — | EP | disclosed |
| US-4371536-A | TRANQUILIZERS | A/S FERROSAN (DK) | 1983-02-01 | — | — | US | disclosed |
| EP-0030254-A1 | Beta-carbolin-3-carboxylic acid derivatives, pharmaceutical compositions containing them and their therapeutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547706-B2 | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and Fragile X syndrome | MECP2, GABBR1, GABBR2 | ALDH1A1 1643/4885MAPT 613/4885KDM4E 4124/4885 |
| US-20140343051-A1 | METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION | MCL1, AHR, MYADM | ALDH1A1 28/4885MAPT 4855/4885KDM4E 1282/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | ALDH1A1 495/4885MAPT 11/4885KDM4E 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.